The 5-year recurrence-free survival rate was 75% in the younger age group and 73% in the older age group. Age may not be a prognostic factor for patients with cervical cancer, according to researchers ...

In the primary efficacy population, the median progression-free survival was not reached in the nivolumab-ipilimumab arm and was 5.9 months in the chemotherapy arm. The combination of nivolumab and ...

Researchers sought to determine the effect of changes in screening guidelines on incidence of breast cancer by stage at diagnosis and surgical management.

Dose-response relationship seen between physical activity and lower rates of cancer progression, all-cause mortality.

At a median follow-up of 12.3 months, 44% of patients with PTCL had an objective response by blinded independent central review in this study, with a median response duration of 11.9 months. Among ...

Prostate cancer treatment guidelines recommend against aggressive therapy for those with a life expectancy of less than 10 years.